CORDA Investment Management LLC. Has $33.97 Million Holdings in Merck & Co., Inc. (NYSE:MRK)

by · The Markets Daily

CORDA Investment Management LLC. lowered its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 3.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 299,090 shares of the company’s stock after selling 9,449 shares during the period. Merck & Co., Inc. makes up approximately 2.6% of CORDA Investment Management LLC.’s holdings, making the stock its 16th biggest position. CORDA Investment Management LLC.’s holdings in Merck & Co., Inc. were worth $33,965,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRK. Itau Unibanco Holding S.A. acquired a new stake in shares of Merck & Co., Inc. in the second quarter worth about $39,000. Abich Financial Wealth Management LLC lifted its position in shares of Merck & Co., Inc. by 121.8% during the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after purchasing an additional 179 shares during the last quarter. Quarry LP acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $42,000. Strategic Financial Concepts LLC lifted its position in shares of Merck & Co., Inc. by 1,475.6% during the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after purchasing an additional 32,832 shares during the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of Merck & Co., Inc. by 47.5% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock worth $43,000 after purchasing an additional 122 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.0 %

NYSE MRK opened at $101.91 on Monday. The firm has a market cap of $258.12 billion, a PE ratio of 21.36, a price-to-earnings-growth ratio of 1.46 and a beta of 0.40. Merck & Co., Inc. has a one year low of $98.60 and a one year high of $134.63. The stock’s 50 day simple moving average is $112.29 and its 200 day simple moving average is $120.81. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.47 and a quick ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The business had revenue of $16.66 billion for the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a return on equity of 37.32% and a net margin of 19.23%. Merck & Co., Inc.’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.13 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRK. Barclays cut their price objective on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, October 7th. BMO Capital Markets cut their price objective on Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating for the company in a research report on Friday. Wells Fargo & Company cut their price objective on Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating for the company in a research report on Friday. Morgan Stanley cut their price target on Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Evercore ISI raised Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $129.93.

View Our Latest Analysis on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories